The Medical Letter on Drugs and Therapeutics
Treatment of Atrial Fibrillation
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The treatment of atrial fibrillation includes anticoagulation, rate control, and rhythm control. New US guidelines for the management of atrial fibrillation have recently been published.1


Atrial fibrillation increases the risk of thromboembolic stroke. Anticoagulant therapy reduces this risk, but it can cause intracranial and other serious bleeding. The risk of bleeding must be weighed against the benefit of thromboembolic risk reduction.

A new scoring system, the CHA2DS2-VASc score, has been designed to aid in this assessment for patients with nonvalvular atrial fibrillation. An algorithm from the recent US guidelines recommends oral anticoagulant treatment for patients who have a CHA2DS2-VASc score ≥2. For patients with a CHA2DS2-VASc score of 0, who have a very low risk of thromboemboli, ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Treatment of Atrial Fibrillation
Article code: 1446a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian